Framing the question and deciding on important outcomesCochrane Handbook for Systematic Reviews of InterventionsNational Cancer Institute Surveillance, Epidemiology, and End Results ProgramSEER*Stat Database: Incidence - SEER 9 Regs Research Data, Nov 2015 Sub (1973-2013) Linked To County Attributes - Total U.S., 1969-2014 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2016, based on the November 2015 submission. Much of the management of older adults with AML is based on single-arm trials or observational studies. Trends in Cardiovascular Medicine provides in depth state-of-the-art reviews of scientific advances in cardiovascular medicine, written and critiqued by internationally known experts. We recommend that as new treatments are evaluated, patient-reported outcomes, quality of life, and assessment of patient goals and preferences be studied.The panel determined that there may be a net benefit of intensive antileukemic therapy over less-intensive antileukemic therapy in older adults with AML who are candidates for intensive antileukemic therapy. Search for other works by this author on: This recommendation applies to patients who are candidates for both intensive and less-intensive antileukemic therapy.This meta-analysis confirms what clinical experience indicates, that intensive and less-intensive chemotherapeutic treatment of AML in older patients has an OS advantage over best supportive care. Policy makers who may be interested in these guidelines include those involved in developing local, national, or international plans with the goal of providing optimal management of older AML patients, including those no longer receiving antileukemic therapy. More-intensive therapy is recommended over less-intensive therapy when deemed tolerable. CiteScore values are based on citation counts in a range of four years (e.g. Discover how our open access options can help you maximize reach and impact Author Guide Author Guide Contents of Blood Advances Author Guide Journal Scope – For specific information detailing Blood Advances’ scope with a newly added category on Health Services and Outcomes. frailty, performance status, functional status and mortality, and quality of life or fatigue for patients with AML 55 years or older receiving antileukemic therapy. This is an important research, health economics, regulatory, and patient satisfaction question, as it offers the opportunity to minimize unnecessary treatment, akin to studies determining duration of anticoagulation therapy following a thromboembolic event.

The panel did not consider these data in depth as part of the recommendations, because results from ongoing randomized trials, with a deeper consideration of toxicities and benefits, are still pending (azacitidine, clinical trial NCT02993523; cytarabine, clinical trial NCT03069352). However, supportive randomized data are not currently available, and the addition of new agents may increase the toxicity of so-called nonintensive therapies. Search for other works by this author on: To decline or learn more, visit our Choice. During deliberations about recommendations, any panel member with a current, direct financial conflict in a commercial entity that marketed any product that could be affected by a specific recommendation participated in discussions about the evidence and clinical context but was recused from making judgments or voting about individual factors (eg, magnitude of desirable consequences) and the direction and strength of the recommendation. The guidelines were then subjected to peer review by ASH guidelines are primarily intended to help clinicians make decisions about diagnostic and treatment alternatives. Moreover, the lack of evidence that such transfusions prolong life for patients at this stage argues that for patients who experience quality-of-life benefits, they are palliative and not disease focused.The studies did not measure burden on patients and caregivers or potential downsides of transfusions. Search for other works by this author on: Sickle cell disease is the most common inherited blood disorder in the United States. We included observational studies in which researchers addressed this question using any type of statistical analysis and in which researchers included at least 50 patients. Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007Cancer survivors in the United States: prevalence across the survivorship trajectory and implications for careAge and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia RegistryImprovements in survival of adults diagnosed with acute myeloblastic leukemia in the early 21st centuryAge-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative GroupPrognostic relevance of integrated genetic profiling in acute myeloid leukemiaAcute myeloid leukemia ontogeny is defined by distinct somatic mutationsPrognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: the Southwest Oncology Group (SWOG) experienceCauses of initial remission induction failure in acute myelogenous leukemiaEfficacy of intensive chemotherapy for acute myelogenous leukemia associated with a preleukemic syndromeAcute myeloid leukemia in the elderly: biological features and search for adequate treatmentTreatment of older patients with acute myeloid leukemia–new agentsOlder adults: should the paradigm shift from standard therapy?Comorbidity and performance status in acute myeloid leukemia patients: a nation-wide population-based cohort studySurvival for older patients with acute myeloid leukemia: a population-based studyMedicare fee-for-service enrollees with primary acute myeloid leukemia: an analysis of treatment patterns, survival, and healthcare resource utilization and costsOutcomes and quality of care in acute myeloid leukemia over 40 yearsThe haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemiaRisk factors and decision criteria for intensive chemotherapy in older patients with acute myeloid leukemiaDevelopment and validation of a novel acute myeloid leukemia-composite model to estimate risks of mortalityGeriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemiaFunction, survival, and care utilization among older adults with hematologic malignanciesPrevalence of cognitive impairment and association with survival among older patients with hematologic cancersGait speed, grip strength, and clinical outcomes in older patients with hematologic malignanciesEscalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720Impact of remission induction chemotherapy on survival in older adults with acute myeloid leukemiaIntensive chemotherapy, azacitidine, or supportive care in older acute myeloid leukemia patients: an analysis from a regional healthcare networkUnited Kingdom National Cancer Research Institute Haematological Oncology Study GroupThe impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trialInternational phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blastsPretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trialPredictive and prognostic markers in adults with acute myeloid leukemia: a single-institution experienceCharacterization and prognostic features of secondary acute myeloid leukemia in a population-based setting: a report from the Swedish Acute Leukemia RegistryFludarabine, cytarabine, and attenuated-dose idarubicin (m-FLAI) combination therapy for elderly acute myeloid leukemia patientsPhase III study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemiaValproic acid in combination with all-trans retinoic acid and intensive therapy for acute myeloid leukemia in older patients [published correction appears in Prognostic significance of risk group stratification in elderly patients with acute myeloid leukaemiaAzacitidine in the treatment of older patients affected by acute myeloid leukemia: a report by the Rete Ematologica Pugliese (REP)Superior long-term outcome with idarubicin compared with high-dose daunorubicin in patients with acute myeloid leukemia age 50 years and olderDisease biology rather than age is the most important determinant of survival of patients > or = 60 years with acute myeloid leukemia treated with uniform intensive therapyHematology Association of South-East Korea (HASEK) Study GroupTherapeutic decision-making in elderly patients with acute myeloid leukemia: conventional intensive chemotherapy versus hypomethylating agent therapyPrognostic significance of NPM1 mutations in the absence of FLT3-internal tandem duplication in older patients with acute myeloid leukemia: a SWOG and UK National Cancer Research Institute/Medical Research Council reportHigh-intensity induction chemotherapy is feasible for elderly patients with acute myeloid leukemiaGeriatric assessment in older patients with acute myeloid leukemia: a retrospective study of associated treatment and outcomesClofarabine plus low-dose cytarabine is as effective as and less toxic than intensive chemotherapy in elderly AML patientsGroupe Francophone des Myélodysplasies (GFM), Acute Leukemia French Association (ALFA); Groupe Ouest-Est des Leucémies Aiguës; Maladies du Sang (GOELAMS)Azacitidine in untreated acute myeloid leukemia: a report on 149 patientsAzacitidine results in comparable outcome in newly diagnosed AML patients with more or less than 30% bone marrow blastsTreatment selection of elderly acute myeloid leukemia patients guided by HCT-CI score [in Chinese]Pretreatment risk factors and importance of comorbidity for overall survival, complete remission, and early death in patients with acute myeloid leukemiaEconomic analysis of blood product transfusions according to the treatment of acute myeloid leukemia in the elderlySurvival from acute myeloid leukaemia in patients over 55 years of age in Northern Ireland: a discrete populationAcute myeloid leukemia in elderly patients: experience of a single centerClinical and epidemiological characteristics of acute myeloid leukemias in adults according to the data of municipal hematology departments in Moscow [in Russian]Treatment outcome in AML: a single-centre experience in an unselected patient cohortAzacitidine might be beneficial in a subgroup of older AML patients compared to intensive chemotherapy: a single centre retrospective study of 227 consecutive patientsAnalysis of efficacy and prognosis of induction chemotherapy in 76 elderly patients with acute myeloid leukemia (non-APL) [in Chinese]Gyeonggi/Incheon Branch, The Korean Society of HematologyClinical characteristics and treatment outcome of acute myeloid leukemia in elderly patients in Korea: a retrospective analysisEfficacy of remission induction chemotherapy and prognostic analysis in elderly patients with acute myeloid leukemia [in Chinese]Gemtuzumab ozogamicin versus best supportive care in older patients with newly diagnosed acute myeloid leukemia unsuitable for intensive chemotherapy: Results of the randomized phase III EORTC-GIMEMA AML-19 TrialDecitabine versus best supportive care in older patients with refractory anemia with excess blasts in transformation (RAEBt) - results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group (GMDSSG)Treatment patterns and comparative analysis of non-intensive regimens in elderly acute myeloid leukemia patients-a real-world experience from IndiaLow-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study GroupTreatment, long-term outcome and prognostic variables in 214 unselected AML patients in SwedenThe management of acute myelogenous leukemia in the elderly: ten-year experience in 118 patientsAcute myeloid leukemia in elderly patients aged over 75 years: experience of a single centre [letter]Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemiaA randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or olderTreatment patterns and comparative effectiveness in elderly acute myeloid leukemia patients (age 70 years or older): the Lyon-university hospital experienceLong-term follow-up of the AML97 study for patients aged 60 years and above with acute myeloid leukaemia: a study of the East German Haematology and Oncology Study Group (OSHO)Selection of elderly acute myeloid leukemia patients for intensive chemotherapy: effectiveness of intensive chemotherapy and subgroup analysisRole of induction and consolidation chemotherapy in elderly acute myeloid leukemia patientsTreatment of elderly patients with acute myeloid leukemia with azacitidine results in fewer hospitalization days and infective complications but similar survival compared with intensive chemotherapyAcute myelogenous leukemia in elderly patients not eligible for intensive chemotherapy: the dark side of the moonAcute nonlymphocytic leukemia in the elderly: results of a retrospective studyComparison of reduced-intensity idarubicin and daunorubicin plus cytarabine as induction chemotherapy for elderly patients with newly diagnosed acute myeloid leukemiaAn evaluation of treatment patterns and outcomes in elderly patients newly diagnosed with acute myeloid leukemia: a retrospective analysis of electronic medical records from US community oncology practicesTreatment of acute myeloid leukemia in the elderly with low-dose cytosine arabinoside [in Danish]Therapeutic outcomes of older patients with acute myeloid leukemiaResponse and survival in acute myeloid leukemia patients not candidates to transplantation treated with azacitidine versus palliative treatment: a retrospective studyTreatment of acute myeloid leukemia in elderly patients.

Submissions are limited to a total of 7 … These guidelines do not address treatment in the relapsed/refractory setting.